直接抗病毒联合治疗时代丙型肝炎治疗优化的相关数据：系统综述和荟萃分析

数据集获取（Figshare）

• 源站标题：Data related to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: systematic review and meta-analysis
• DOI：10.6084/m9.figshare.9636983.v1
• 发布日期：2019-08-23
• 文件数：7 个
• 文件总体积：1.32 MB
• 源站页面：https://springernature.figshare.com/articles/dataset/Data_related_to_treatment_optimisation_for_hepatitis_C_in_the_era_of_combination_direct-acting_antiviral_therapy_systematic_review_and_meta-analysis/9636983

命令行下载

curl -L -o "Supplementary Figure 1.tif" "https://ndownloader.figshare.com/files/17288609"
curl -L -o "Supplementary Tables 1-6.docx" "https://ndownloader.figshare.com/files/17288600"
curl -L -o "PRISMA 2009 checklist.doc" "https://ndownloader.figshare.com/files/17288597"
curl -L -o "HCV Treatment Optimisation Stata do file.do" "https://ndownloader.figshare.com/files/17288594"
curl -L -o "HCV treatment optimisation meta-analysis data sheet.xlsx" "https://ndownloader.figshare.com/files/17288591"
curl -L -o "Supplementary Figure 2.pdf" "https://ndownloader.figshare.com/files/17385467"
curl -L -o "Supplementary Figure 3.pdf" "https://ndownloader.figshare.com/files/17385470"

文件清单

• Supplementary Figure 1.tif（261.06 KB）
• Supplementary Tables 1-6.docx（193.98 KB）
• PRISMA 2009 checklist.doc（64.51 KB）
• HCV Treatment Optimisation Stata do file.do（16.26 KB）
• HCV treatment optimisation meta-analysis data sheet.xlsx（42.55 KB）
• Supplementary Figure 2.pdf（498.91 KB）
• Supplementary Figure 3.pdf（244.38 KB）

文件总体积 1.32 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy:

• Supplementary
  figure 1: Thematic
  map exploring strategies for treatment optimisation. The duration, combination
  and/or dose of a treatment regimen is optimised for the individual receiving
  therapy. Abbreviations: RBV - ribavirin; DAA - direct-acting antiviral; IFN -
  interferon.

• Supplementary figure 2: Cochrane risk of bias tool for randomised controlled trials
  summary - review authors’’ judgements about each risk of bias item for each
  included study. Prepared using Cochrane Review Manager v5.3 (RevMan, RRID:SCR_003581).

• Supplementary figure 3: Risk of bias graph - review authors’’ judgements about each risk of
  bias item presented as percentages across all included studies. Prepared using Cochrane Review Manager v5.3 (RevMan, RRID:SCR_003581).

• Prisma
  2009 Checklist: Completed
  checklist providing page numbers in the associated manuscript for the location of each element of the Prisma
  2009 checklist.

• HCV
  Treatment Optimisation Stata .do file: This is the .do file used to process and
  analyse the data. The proprietary statistical software ‘‘Stata’’ was used to create this file.

• HCV
  Treatment Optimisation Meta-analysis Data Sheet: This is the data
  extracted from trials included in this meta-analysis. The file was imported
  into Stata for analysis using the included .do file.

• Supplementary Tables 1-6.docx:
  This single Word document contains the following 6 tables:

  • Supplementary table 1: Summary of Ovid search strategy - Medline and Embase. Last conducted on 4th July 2019.

  • Supplementary table 2: Individual study characteristics. The factors used for stratification or personalisation, treatment strategy adopted, and resultant SVR rates (intention-to-treat and per protocol) are presented for each treatment arm.

  • Supplementary table 3: Meta-regression - ‘maintain SVR group’. Clinical and methodological variables were subject to univariable random effects meta-regression. Only those variables with p≤0·1 on univariable analysis were carried forward to the multivariabl

许可

CC0

引用

学术使用请引用 DOI 10.6084/m9.figshare.9636983.v1（source: https://springernature.figshare.com/articles/dataset/Data_related_to_treatment_optimisation_for_hepatitis_C_in_the_era_of_combination_direct-acting_antiviral_therapy_systematic_review_and_meta-analysis/9636983）。